|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | MicroRNAs in pancreatic ductal adenocarcinoma显示文摘Ductal adenocarcinoma of the pancreas is a lethal cancer for which the only chance of long-term survival belongs to the patient with localized disease in whom a potentially curative resection can be done. Therefore, biomarkers for early detection and new therapeutic strategies are urgently needed. miRNAs are a recently discovered class of small endogenous non-coding RNAs of about 22 nucleotides that have gained attention for their role in downregulation of mRNA expression at the post-transcriptional level. miRNAs regulate proteins involved in critical cellular processes such as differentiation, proliferation, and apoptosis. Evidence suggests that deregulated miRNA expression is involved in carcinogenesis at many sites, including the pancreas. Aberrant expression of miRNAs may upregulate the expression of oncogenes or downregulate the expression of tumor suppressor genes, as well as play a role in other mechanisms of carcinogenesis. The purpose of this review is to summarize our knowledge of deregulated miRNA expression in pancreatic cancer and discuss the implication for potential translation of this knowledge into clinical practice. | Jong Y Park James Helm Domenico Coppola Donghwa Kim Mokenge Malafa Seung Joon Kim | 2011 | World Journal of Gastroenterology2011，17，7： | 7 |
| 2 | Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolization显示文摘AIM To evaluate the value of pre-treatment 18F-FDG PET/CT in patients with HCC following liver radioembolization.METHODS We identified 34 patients with HCC who underwent an FDG PET/CT scan prior to hepatic radioembolization at our institution between 2009 and 2013. Patients wereseen in clinic one month after radioembolization and then at 2-3 mo intervals. We assessed the influence of FDG tumor uptake on outcomes including local liver control(LLC), distant liver control(DLC), time to distant metastases(DM), progression free survival(PFS) and overall survival(OS).RESULTS The majority of patients were males(n = 25, 74%), and had Child Pugh Class A(n = 31, 91%), with a median age of 68 years(46-84 years). FDG-avid disease was found in 19(56%) patients with SUVmax ranging from 3 to 20. Female patients were more likely to have an FDG-avid HCC(P = 0.02). Median follow up of patients following radioembolization was 12 months(1.2-62.8 mo). FDG-avid disease was associated with a decreased 1 year LLC, DLC, DM and PFS(P < 0.05). Using multivariate analysis, FDG avidity predicted for LLC, DLC, and PFS(all P < 0.05).CONCLUSION In this retrospective study, pre-treatment HCC FDGavidity was found to be associated with worse LLC, DLC, and PFS following radioembolization. Larger studies are needed to validate our initial findings to assess the role of F-18-FDG PET/CT scans as biomarker for patients with HCC following radioembolization. | Yazan Abuodeh Arash O Naghavi Kamran A Ahmed Puja S Venkat Youngchul Kim Bela Kis Junsung Choi Benjamin Biebel Jennifer Sweeney Daniel A Anaya Richard Kim Mokenge Malafa Jessica M Frakes Sarah E Hoffe Ghassan El-Haddad | 2016 | World Journal of Gastroenterology2016，22，47： | 3 |
| 3 | Minimally invasive image-guided therapy of primary and metastatic pancreatic cancer显示文摘Pancreatic cancer is a challenging malignancy with limited treatment options and poor life expectancy.The only curative option is surgical resection,but only 15%-20%of patients are resectable at presentation because more than 50%of patients has distant metastasis at diagnosis and the rest of them has locally advanced pancreatic cancer(LAPC).The standard of care first line treatment for LAPC patients is chemotherapy with or without radiation therapy.Recent developments in minimally invasive ablative techniques may add to the treatment armamentarium of LAPC.There are increasing number of studies evaluating these novel ablative techniques,including radiofrequency ablation,microwave ablation,cryoablation and irreversible electroporation.Most studies which included pancreatic tumor ablation,demonstrated improved overall survival in LAPC patients.However,the exact protocols are yet to set up to which stage of the treatment algorithm ablative techniques can be added and in what kind of treatment combinations.Patients with metastatic pancreatic cancer has dismal prognosis with 5-year survival is only 3%.The most common metastatic site is the liver as 90%of pancreatic cancer patients develop liver metastasis.Chemotherapy is the primary treatment option for patients with metastatic pancreatic cancer.However,when the tumor is not responding to chemotherapy or severe drug toxicity develops,locoregional liver-directed therapies can provide an opportunity to control intrahepatic disease progression and improve survival in selected patients.During the last decade new therapeutic options arose with the advancement of minimally invasive technologies to treat pancreatic cancer patients.These new therapies have been a topic of increasing interest due to the severe prognostic implications of locally advanced and metastatic pancreatic cancer and the low comorbid risk of these procedures.This review summarizes new ablative options for patients with LAPC and percutaneous liver-directed therapies for patients with liver-dominant metastatic disease. | Andras Bibok Dae Won Kim Mokenge Malafa Bela Kis | 2021 | World Journal of Gastroenterology2021，27，27： | 3 |
| 4 | CDX2 protein expression compared to alcian blue staining in the evaluation of esophageal intestinal metaplasia显示文摘AIM:To compare the sensitivity and specificity of CDX2 and alcian blue(AB) p H 2.5 staining in identifying esophageal intestinal metaplasia.METHODS:One hundred and ninty-nine biopsies from 186 patients were retrospectively reviewed and categorized as Barrett's esophagus(BE)(n =108); non-Barrett's esophagus(NBE)(n =48); columnar blue cells(CB) and esophageal glands(EG)(n =43).The biopsies were stained with AB and immunostained for CDX2 using a mouse monoclonal antibody from Biogenex(clone CDX2-88) and the Ventana Discovery X automated immunostainer.The positive and negative predictive value of each group was used to determine the predictive power of CDX2 and AB in diagnosing intestinal metaplasia.RESULTS:All of the 108 BE biopsies(100%) were positive for AB and 102 of them(94.4%) were positive for CDX2.The six BE patients(5.6%) who failed to stain with CDX2 were found to have lost the focus of intestinal metaplasia upon deeper sectioning for immunostaining.Both AB and CDX2 were negative in 43 out of 48(89.6%) NBE cases.Five NBE patients(10.4%) were falsely positive for AB due to the presence of EG and CB in these biopsies.These cases were all CDX2 negative.In addition,5 AB negative NBE were found to be CDX2 positive.Based on these results the CDX2 immunostain had similar sensitivity but higher specificity(100% vs about 91%) than AB in detecting intestinal type metaplasia in these samples.Our data shows that CDX2 has a better PPV in detecting intestinal metaplasia as compared to AB(95.6% vs 71.5%,respectively).CONCLUSION:CDX2 has a better positive predictive value than AB in detecting intestinal metaplasia.CDX2may be useful when challenged by gastro-esophageal biopsies containing mimikers of BE. | Dennis R Johnson Maisoun Abdelbaqui Maryam Tahmasbi Zoltan Mayer Hung-Wei Lee Mokenge P Malafa Domenico Coppola | 2015 | World Journal of Gastroenterology2015，21，9： | 2 |
| 5 | Chronic alcohol-induced oxidative endothelial injury relates to angiotensin II levels in the rat显示文摘 | Kazim Husain Manuel Vazquez Rais A. Ansari Mokenge P. Malafa Jainarine Lalla | 2008 | Molecular and Cellular Biochemistry (-)2008，，1： | 2 |
| 6 | Stereotactic Body Radiation Therapy for Locally Advanced and Borderline Resectable Pancreatic Cancer Is Effective and Well Tolerated显示文摘 | Michael D. Chuong Gregory M. Springett Jessica M. Freilich Catherine K. Park Jill M. Weber Eric A. Mellon Pamela J. Hodul Mokenge P. Malafa Kenneth L. Meredith Sarah E. Hoffe Ravi Shridhar | 2013 | International Journal of Radiation Oncology Biology Physics2013，，3： | 1 |
| 7 | PET/CT Fusion Scan Enhances CT Staging in Patients with Pancreatic Neoplasms显示文摘 | Jeffrey M. Farma MD Alfredo A. Santillan MD MPH Marcovalerio Melis MD Janet Walters RN CCM Daly Belinc RN BSN Dung-Tsa Chen PhD Edward A. Eikman MD Mokenge Malafa MD | 2008 | Annals of Surgical Oncology2008，，9： | 1 |
| 8 | PET/CT Fusion Scan Enhances CT Staging in Patients with Pancreatic Neoplasms显示文摘 | Jeffrey M. Farma MD Alfredo A. Santillan MD MPH Marcovalerio Melis MD Janet Walters RN CCM Daly Belinc RN BSN Dung-Tsa Chen PhD Edward A. Eikman MD Mokenge Malafa MD | 2008 | Annals of Surgical Oncology2008，，9： | 1 |
| 9 | PET/CT Fusion Scan Enhances CT Staging in Patients with Pancreatic Neoplasms显示文摘 | Jeffrey M. Farma Alfredo A. Santillan Marcovalerio Melis Janet Walters Daly Belinc Dung-Tsa Chen Edward A. Eikman Mokenge Malafa | 2008 | Annals of Surgical Oncology2008，，： | 1 |
| 10 | Plasma MicroRNAs as Novel Biomarkers for Patients with Intraductal Papillary Mucinous Neoplasms of the Pancreas显示文摘 | Jennifer Permuth-Wey Dung-Tsa Chen William J. Fulp Sean J. Yoder Yonghong Zhang Christina Georgeades Kazim Husain Barbara Ann Centeno Anthony M. Magliocco Domenico Coppola Mokenge Malafa | 2015 | Cancer Prevention Research2015，，9： | 1 |
| 11 | Vitamins in pancreatic cancer: a review of underlying mechanisms and future applications 显示文摘 | Davis-Yadley Ashley H Mokenge P Malafa | 2015 | Advances in nutrition2015，6，6： | 1 |
| 12 | Inhibition of Angiogenesis and Promotion of Melanoma Dormancy by Vitamin E Succinate显示文摘 | Mokenge PM Ffida DF LaKesha S | 2002 | Ann Surg Oncol2002，9，10： | 1 |
| 13 | Chronic alcohol-induced oxidative endothelial injury relates to angiotensin II levels in the rat显示文摘 | Kazim Husain Manuel Vazquez Rais A. Ansari Mokenge P. Malafa Jainarine Lalla | 2008 | Molecular and Cellular Biochemistry (-)2008，，1： | 1 |
| 14 | Stereotactic Body Radiation Therapy for Locally Advanced and Borderline Resectable Pancreatic Cancer Is Effective and Well Tolerated显示文摘 | Michael D. Chuong Gregory M. Springett Jessica M. Freilich Catherine K. Park Jill M. Weber Eric A. Mellon Pamela J. Hodul Mokenge P. Malafa Kenneth L. Meredith Sarah E. Hoffe Ravi Shridhar | 2013 | International Journal of Radiation Oncology, Biology, Physics2013，，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员